Evidence map›Paper›PMID 42310909›Full record

Trial reportDiabetes, obesity & metabolism2026

Pharmacokinetics and Food Effect of HDM1002, a Novel Oral Small-Molecule GLP-1 Receptor Agonist, in Healthy Chinese Volunteers: A Bioequivalence Study.

Chunqi Huang, Yiyang Ying, Yi Wu, Shufan Cai, Lijun Ye, Xiangxin Huang, Lin Wang, Ying Wang

Abstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chunqi HuangDepartment of Laboratory Medicine, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0002-8667-0034
Yiyang YingThe First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yi WuClinical Research Center, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
Shufan CaiClinical Research Center, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
Lijun YeClinical Research Center, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
Xiangxin HuangClinical Research Center, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
Lin WangClinical Research Center, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
Ying WangClinical Research Center, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.

Funding

Education Department Foundation of Zhejiang Province Y202044779Key Research and Development Program of Zhejiang Province WKJ-ZJ-1914National Natural Science Foundation of China 81971172Zhejiang Provincial Outstanding Youth Science Foundation LR21H090001
6 · The paper itself

Abstract

purposeHDM1002 is a potent, orally active, and highly selective small-molecule full agonist of the glucagon-like peptide-1 receptor (GLP-1R), independently developed by Hangzhou Sino-American Huadong Pharmaceutical Co. Ltd. Our aim was to evaluate the pharmacokinetics, relative bioavailability, and food effects of two tablet strengths (100 and 200 mg) of HDM1002 in Chinese health volunteers (HVs).

methodsThis single-centre, randomised, open-label, single-dose, two-formulation, three-period, double-crossover phase I study enrolled 33 HVs. All subjects received each of the following three treatments in different periods: (A) two 100-mg tablets under fasting conditions; (B) a single 200-mg tablet under fasting conditions; and (C) a single 200-mg tablet following a high-fat meal. A washout period of 7 days was implemented. The plasma concentrations of HDM1002 were measured using HPLC-MS/MS method, and PK parameters were determined by non-compartmental analysis.

resultsUnder fasting conditions, the 90% confidence intervals (CI) for the geometric mean ratios (two 100-mg tablets vs. one 200-mg tablet) of C

conclusionHDM1002 was well-tolerated and safe. The two tablet strengths (100 and 200 mg) were bioequivalent under fasting conditions. A high-fat meal modestly reduced the C

trial registrationClinicalTrials.gov identifier: ChiCTR2500111569.

Indexed as

Food-Drug InteractionsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsAdministration, OralAdultArea Under CurveBiological AvailabilityChinaCross-Over StudiesEast Asian PeopleFastingFemaleGlucagon-Like Peptide-1 ReceptorHealthy VolunteersHumansMaleGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsTabletsbioequivalenceGLP‐1 receptor agonistHDM1002novel oral small‐moleculepharmacokineticssafety

Identifiers

PMID42310909
PMCPMC13448887

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.